泽尼达妥单抗的用法用量

Zenidatumab is the world's first bispecific antibody therapy for HER2-positive biliary tract cancer, and its standardized use is crucial to the therapeutic effect. This article will introduce in detail the standard usage and dosage of this drug, possible side effects, and medication precautions for special groups, providing a reference for clinical medication.

Usage and Dosage of Zenidatuzumab

The dosage regimen of Zenidatuzumab needs to strictly follow the guideline requirements. From patient screening to specific administration, it requires a professional medical team.

Patient screening criteria

HER2-positive (IHC3+) status must be confirmed by an FDA-approved testing method and is applicable to patients with unresectable or metastatic biliary tract cancer who have progressed after previously receiving gemcitabine-containing chemotherapy.

Dosage schedule

The recommended dose is 20mg/kg, intravenous infusion once every 2 weeks. The first and second infusion time is 120-150 minutes, and subsequent infusion times can be shortened to 90 minutes and 60 minutes if well tolerated.

Drug preparation requirements

Each bottle of 300 mg should be reconstituted with 5.7 mL of sterile water for injection, with a final concentration of 50 mg/mL. After dilution, the concentration of the solution should be controlled at 0.4-6 mg/mL, and a 0.2-micron filter should be used for intravenous infusion.

Patients need to standardize the medication process under the guidance of professional medical personnel.

Side effects of zenidatuzumab

Zenidatuzumab treatment may cause multi-system adverse reactions, which requires close monitoring and timely intervention.

Common adverse reactions

Gastrointestinal reactions are the most common, including diarrhea and abdominal pain, and systemic symptoms such as fatigue and rash are also common.

Serious adverse reactions

Include left ventricular dysfunction, infusion-related reactions, and interstitial lung disease, which may require suspension or discontinuation of treatment.

Laboratory abnormalities

Reduced hemoglobin, lymphopenia and abnormal liver function indicators are common.

Timely identification and treatment of adverse reactions is of great significance to ensure the continuity of treatment.

Usage of zenidatuzumab for special groups

Special attention needs to be paid to individualized adjustments when using zenidatuzumab for different groups of people.

Pregnant women

Absolutely prohibited. It may cause serious malformations such as oligohydramnios and lung hypoplasia in the fetus. Pregnancy status must be confirmed before taking the medication, and reliable contraceptive measures must be taken during treatment.

Elderly patients

In clinical studies, 49% of patients were ≥65 years old. The safety and effectiveness are comparable to those of younger patients, but cardiovascular function still needs to be closely monitored.

Patients with hepatic and renal insufficiency

The current instructions do not provide clear suggestions for dosage adjustment, and clinical use must be carefully adjusted according to the specific conditions of the patient.

Medicine use in special populations requires more careful monitoring and individualized treatment plans to balance efficacy and safety.